Bradley (Brad) J. Stish, M.D.

  1. Radiation Oncologist

Publications

  1. Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE. The current state of randomized clinical trial evidence for prostate brachytherapy. Urol Oncol. 2019 Sep; 37 (9):599-610 Epub 2019 May 03
    View PubMed
  2. Merrell KW, Davis BJ, Goulet CC, Furutani KM, Mynderse LA, Harmsen WS, Wilson TM, McLaren RH, Deufel CL, Birckhead BJ, Funk RK, McMenomy BP, Stish BJ, Choo CR. Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds. Brachytherapy. 2019 May - Jun; 18 (3):306-312 Epub 2019 Mar 08
    View PubMed
  3. Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo R, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ. Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. Adv Radiat Oncol. 2019 Apr-Jun; 4 (2):314-322 Epub 2019 Feb 19
    View PubMed
  4. Routman DM, Funk RK, Stish BJ, Mynderse LA, Wilson TM, McLaren R, Harmsen WS, Mara K, Deufel CL, Furutani KM, Haddock MG, Pisansky TM, Choo CR, Davis BJ. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients. Brachytherapy. 2019 Jan - Feb; 18 (1):1-7 Epub 2018 Oct 04
    View PubMed
  5. Evans JD, Morris LK, Zhang H, Cao S, Liu X, Mara KC, Stish BJ, Davis BJ, Mansfield AS, Dronca RS, Iott MJ, Kwon ED, Foote RL, Olivier KR, Dong H, Park SS. Prospective Immunophenotyping of CD8(+) T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. Int J Radiat Oncol Biol Phys. 2019 Jan 1; 103 (1):229-240 Epub 2018 Sept 08
    View PubMed
  6. Welch BT, Packard AT, Atwell TD, Johnson GB, Lowe VJ, Karnes RJ, Mynderse LA, Gunderson TM, Park SS, Stish BJ, Evans JD, Kwon ED, Davis BJ, Nathan MA. Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications. Adv Radiat Oncol. 2019 Jan-Mar; 4 (1):79-89 Epub 2018 Sept 05
    View PubMed
  7. Gao RW, Park SS, Jakub JW, Hieken TJ, Conners AL, Neal L, Pruthi S, Corbin KS, Yan ES, Mutter RW, Stish BJ. Durable response of early-stage breast cancer to bilateral definitive SBRT in a medically inoperable patient. Pract Radiat Oncol. 2018 Nov - Dec; 8 (6):361-365 Epub 2018 Mar 18
    View PubMed
  8. Stish BJ, Davis BJ, Mynderse LA, McLaren RH, Deufel CL, Choo R. Low dose rate prostate brachytherapy. Transl Androl Urol. 2018 Jun; 7 (3):341-356
    View PubMed
  9. De Bari B, Stish B, Ball MW, Habboush Y, Sargos P, Krengli M, Bossi A, Stabile A, Sole Pesutic C, Lestrade L, Smeenk RJ, Jereczek-Fossa BA, Zilli T, Crehange G, Alongi F, Zaorsky N, Ozsahin M. Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study. Prostate. 2017 Jul; 77 (10):1160-1166 Epub 2017 June 08
    View PubMed
  10. Stish BJ, Davis BJ, Mynderse LA, Deufel CL, Choo R. Brachytherapy in the Management of Prostate Cancer. Surg Oncol Clin N Am. 2017 Jul; 26 (3):491-513 Epub 2017 May 11
    View PubMed
  11. Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ. Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. Int J Radiat Oncol Biol Phys. 2017 Mar 1; 97 (3):526-535 Epub 2016 Nov 17
    View PubMed
  12. Pisansky TM, Stish BJ. Reply to N. Fossati et al. J Clin Oncol 2017 Feb; 35 (4):470-471 Epub 2016 Nov 07
    View PubMed
  13. Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, Buskirk SJ. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. J Clin Oncol. 2016 Nov 10; 34 (32):3864-3871
    View PubMed
  14. Stish BJ, Pafundi DH, Hieken TJ, Whitaker TJ, Furutani KM, Jakub JW, Boughey JC, Degnim AC, McLemore LB, Mou B, Mutter RW, Park SS. Feasibility and full-course dosimetry of an intraoperatively placed multichannel brachytherapy catheter for accelerated partial breast irradiation. Brachytherapy. 2016 Nov - Dec; 15 (6):796-803 Epub 2016 Sept 07
    View PubMed
  15. Stish BJ, Pafundi DH, Hieken TJ, Whitaker TJ, Furutani KM, Jakub JW, Boughey JC, Degnim AC, McLemore LB, Mou B, Mutter RW, Park SS. Feasibility and full-course dosimetry of an intraoperatively placed multichannel brachytherapy catheter for accelerated partial breast irradiation Brachytherapy. 2016 Nov-dec; 15: (6)796-803.
  16. Stish BJ, Ahmed SK, Rose PS, Arndt CA, Laack NN. Patient-Reported Functional and Quality of Life Outcomes in a Large Cohort of Long-Term Survivors of Ewing Sarcoma. Pediatr Blood Cancer. 2015 Dec; 62 (12):2189-96 Epub 2015 Aug 14
    View PubMed
  17. Stish BJ, Hallemeier CL, Olivier KR, Harmsen WS, Allen MS, Garces YI. Long-Term Outcomes and Patterns of Failure After Surgical Resection of Small-Cell Lung Cancer. Clin Lung Cancer. 2015 Sep; 16: (5)e67-73.
    View PubMed
  18. Stish BJ, Oh S, Vikers SM, Buchsbaum DJ, Saluja AK, Vallera DA. A new drug delivery method of bispecific lignad-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer Pancreas.;()913-22.
  19. Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA. Design and modification of EGF4KDEL 7 Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity Br J Cancer.2009;1114-23.
  20. Stish BJ, Oh S, Sachdev D, Chen H, Dudek AZ, Vallera DA. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma Clin Cancer Res.2009;6137-47.
  21. Vallera DA, Stish BJ, Shu Y, Chen H, Saluja A, Buchsbaum DJ, Vikers SM. Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL 13 and EGF receptors in a mouse xenograft model Gut..2008;634-41.
  22. Stish BJ, Oh S, Vallera DA. Anti-globlastoma eddect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model J Neurooncol.2008;51-61.
  23. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer Clin Cancer Res..11/13/2007;6486-93.
  24. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv Clin Cancer Res..5/13/2007;3058-67.
PST-20340351